Free Trial
NASDAQ:ADVM

Adverum Biotechnologies (ADVM) Stock Price, News & Analysis

Adverum Biotechnologies logo
$2.38 +0.13 (+5.53%)
Closing price 07/3/2025 02:21 PM Eastern
Extended Trading
$2.33 -0.05 (-2.31%)
As of 07/3/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Adverum Biotechnologies Stock (NASDAQ:ADVM)

Key Stats

Today's Range
$2.26
$2.34
50-Day Range
$2.05
$3.59
52-Week Range
$1.78
$10.14
Volume
73,586 shs
Average Volume
266,840 shs
Market Capitalization
$49.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.80
Consensus Rating
Moderate Buy

Company Overview

Adverum Biotechnologies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
82nd Percentile Overall Score

ADVM MarketRank™: 

Adverum Biotechnologies scored higher than 82% of companies evaluated by MarketBeat, and ranked 190th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Adverum Biotechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Adverum Biotechnologies has only been the subject of 4 research reports in the past 90 days.

  • Read more about Adverum Biotechnologies' stock forecast and price target.
  • Earnings Growth

    Earnings for Adverum Biotechnologies are expected to decrease in the coming year, from ($4.92) to ($5.20) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Adverum Biotechnologies is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Adverum Biotechnologies is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Adverum Biotechnologies has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Adverum Biotechnologies' valuation and earnings.
  • Percentage of Shares Shorted

    13.30% of the float of Adverum Biotechnologies has been sold short.
  • Short Interest Ratio / Days to Cover

    Adverum Biotechnologies has a short interest ratio ("days to cover") of 5.5.
  • Change versus previous month

    Short interest in Adverum Biotechnologies has recently decreased by 5.15%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Adverum Biotechnologies does not currently pay a dividend.

  • Dividend Growth

    Adverum Biotechnologies does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.30% of the float of Adverum Biotechnologies has been sold short.
  • Short Interest Ratio / Days to Cover

    Adverum Biotechnologies has a short interest ratio ("days to cover") of 5.5.
  • Change versus previous month

    Short interest in Adverum Biotechnologies has recently decreased by 5.15%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Adverum Biotechnologies this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for ADVM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Adverum Biotechnologies insiders have bought 472.64% more of their company's stock than they have sold. Specifically, they have bought $149,000.00 in company stock and sold $26,020.00 in company stock.

  • Percentage Held by Insiders

    Only 6.00% of the stock of Adverum Biotechnologies is held by insiders.

  • Percentage Held by Institutions

    48.17% of the stock of Adverum Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Adverum Biotechnologies' insider trading history.
Receive ADVM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adverum Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

ADVM Stock News Headlines

Adverum Biotechnologies, Inc. (ADVM) - Yahoo Finance
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
See More Headlines

ADVM Stock Analysis - Frequently Asked Questions

Adverum Biotechnologies' stock was trading at $4.67 at the start of the year. Since then, ADVM shares have decreased by 48.9% and is now trading at $2.3850.

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) released its quarterly earnings data on Tuesday, April, 15th. The biotechnology company reported ($1.96) earnings per share for the quarter, missing the consensus estimate of ($1.34) by $0.62.

Adverum Biotechnologies's stock reverse split on Thursday, March 21st 2024.The 1-10 reverse split was announced on Thursday, March 21st 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of ADVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Adverum Biotechnologies investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
4/15/2025
Today
7/06/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ADVM
Employees
190
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.80
High Stock Price Target
$40.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+897.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$130.93 million
Pretax Margin
-15,079.90%

Debt

Sales & Book Value

Annual Sales
$1 million
Price / Cash Flow
N/A
Book Value
$3.40 per share
Price / Book
0.70

Miscellaneous

Free Float
19,638,000
Market Cap
$49.82 million
Optionable
Optionable
Beta
0.70

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:ADVM) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners